Prevalence and clinical significance of RBM3 immunostaining in non-small cell lung cancers
| Autor: | Jakob R. Izbicki, Nathaniel Melling, Kai Bachmann, Matthias Reeh, Marco Blessmann, Oliver Mann, Katharina Grupp, Alexander T. El Gammal, Christoph Moebius, Bianca T. Hofmann |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male 0301 basic medicine Subset Analysis Cancer Research Pathology medicine.medical_specialty Lung Neoplasms 03 medical and health sciences 0302 clinical medicine Carcinoma Non-Small-Cell Lung Biomarkers Tumor Prevalence medicine Humans Clinical significance Aged Neoplasm Staging Aged 80 and over Tissue microarray business.industry RNA-Binding Proteins General Medicine Middle Aged medicine.disease Immunohistochemistry respiratory tract diseases Staining 030104 developmental biology Oncology Tissue Array Analysis 030220 oncology & carcinogenesis Large-cell lung carcinoma Adenocarcinoma Female business Immunostaining |
| Zdroj: | Journal of Cancer Research and Clinical Oncology. 145:873-879 |
| ISSN: | 1432-1335 0171-5216 |
| DOI: | 10.1007/s00432-019-02850-1 |
| Popis: | Aberrant expression of RNA-binding motif protein 3 (RBM3) has been suggested as a prognostic biomarker in several malignancies. This study was performed to analyse the prevalence and clinical significance of RBM3 immunostaining in non-small cell lung cancers (NSCLCs). Therefore, we took advantage of our tissue microarray (TMA) containing more than 600 NSCLC specimens. While nuclear RBM3 staining was always high in normal lung tissue, high RBM3 staining was only seen in 77.1% of 467 interpretable non-metastatic NSCLCs. Reduced RBM3 staining was significantly associated with advanced pathological tumor stage (pT) in NSCLCs (p = 0.0031). Subset analysis revealed that the association between reduced RBM3 staining and advanced pT stage was largely driven by the histological subgroup of lung adenocarcinoma (LUACs) (p = 0.0036). In addition, reduced RBM3 expression predicted shortened survival in LUAC patients (p = 0.0225). In summary, our study shows that loss of RBM3 expression predicts worse clinical outcome in LUAC patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink